| Budget Amount *help |
¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Outline of Final Research Achievements |
The main purpose of this study was to develop a new delivery system for intraperitoneal administration of anti-cancer agents (ACA) against peritoneal dissemination that can reduce systemic toxicity and achieve high dose chemotherapy. As a carrier of ACAs, microspheres were prepared from gelatin of a non-toxic and biodegradable material for the sustained release of CDDP. The gelatin hydrogel microspheres incorporating CDDP (GM-CDDP) were able to release CDDP in the peritoneal cavity as a result of gelatin biodegradation. GM-CDDP was injected intraperitoneally into a mouse model of a peritoneal dissemination; their therapeutic efficacy and adverse effects were evaluated. Gelatin hydrogel microspheres decreased the adverse effects of CDDP and allowed high dose intraperitoneal chemotherapy for peritoneal dissemination of cancer cells due to controlled CDDP release. Currently, we are performing experiments for optimization of this carrier of ACAs for better clinical applications.
|
